Objective: Individuals who experience interpersonal trauma (e.g., intimate partner violence, sexual assault, and adverse childhood experiences) are disproportionately affected by the opioid epidemic; however, not all will engage in opioid misuse behaviors. Personal resources, such as coping, social support, and self-efficacy, may attenuate the negative effects of trauma and foster resiliency. This study examines how personal resources affect opioid misuse among individuals with a history of interpersonal trauma.
Method: Data were collected from a convenience sample ( = 236) through a cross-sectional, self-report survey. Latent profile analysis identified subgroups with different personal resource profiles based on coping behaviors, social support, and health-related self-efficacy. Logistic regression examined subgroup differences in sociodemographics and opioid misuse behaviors.
Results: Results supported a 3-class (low, moderate, and high personal resource groups) and 4-class model (low, internal, external, and high resource groups). Males, African Americans, and Hispanics were more likely to have low resource profiles. Low resource groups had the highest probability of reporting opioid misuse; however, there were no significant between-class differences after adjusting for depressive symptoms, pain intensity, sex, race/ethnicity, and age. Pain intensity and depressive symptoms largely accounted for subgroup differences in opioid misuse.
Conclusions: Findings suggest that sex and race/ethnicity play an important role in the personal resource profiles of individuals with a history of interpersonal trauma. Interventions to promote resiliency and mitigate the effects of trauma on opioid misuse should consider personal resource profiles, mental health, and effective pain management. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1037/tra0001089 | DOI Listing |
J Subst Use Addict Treat
January 2025
Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, 1070 Arastradero Road, Palo Alto, CA 94304, United States of America. Electronic address:
Background: Opioid-related overdoses increased substantially during the COVID-19 pandemic, eliciting an urgent demand for accessible treatment for individuals with opioid use disorder (OUD) and those who support them (support persons). Support persons can improve treatment initiation and retention in their individuals with OUD. Additionally, support persons may have their own mental health needs related to their loved one's OUD.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Legal Medicine, Department of Medical, Surgical and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.
Fentanyl is a synthetic opioid widely used for its potent analgesic effects in chronic pain management and intraoperative anesthesia. However, its high potency, low cost, and accessibility have also made it a significant drug of abuse, contributing to the global opioid epidemic. This review aims to provide an in-depth analysis of fentanyl's medical applications, pharmacokinetics, metabolism, and pharmacogenetics while examining its adverse effects and forensic implications.
View Article and Find Full Text PDFEpidemiology
January 2025
Department of Statistical Sciences, College of Arts and Sciences, Wake Forest University, Winston-Salem, North Carolina.
Background: The overdose epidemic remains largely driven by opioids, but county-level prevalence of opioid misuse is unknown. Without this information, public health and policy responses are limited by a lack of knowledge on the scope of the problem.
Methods: Using an integrated abundance model, we estimate annual county-level prevalence of opioid misuse for counties in North Carolina from 2016 to 2021.
JAMA Netw Open
January 2025
San Francisco Department of Public Health, San Francisco, California.
Importance: The rise of high-potency opioids such as fentanyl makes buprenorphine initiation challenging due to the risks of precipitated withdrawal, prompting the exploration of strategies, such as low-dose initiation (LDI) of buprenorphine. However, no comparative studies on LDI outcomes exist.
Objective: To evaluate outpatient outcomes associated with 2 LDI protocols of buprenorphine among individuals with opioid use disorder (OUD) using fentanyl.
Nat Commun
January 2025
Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA, US.
The opioid crisis, driven by synthetic opioids like fentanyl, demands innovative solutions. The opioid antidote naloxone has a short action ( ~ 1 hour), requiring repeated doses. To address this, we present a new and simple naloxone prodrug delivery system repurposing a hydrophilic derivative of acoramidis, a potent transthyretin ligand.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!